Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

Area of Science:

• Immunology
• Oncology
• Autoimmunity

Background:

• Clinical trials are exploring immunotherapies targeting specific pathways to enhance cancer treatment and manage autoimmune diseases.
• Immune-checkpoint inhibitors, particularly anti-CTLA-4 (e.g., ipilimumab), are investigated for their efficacy and associated immune-related adverse events (irAEs).
• Despite irAEs in ~60% of patients, ipilimumab demonstrates an average 3-5 year overall survival of 22-25%.

Purpose of the Study:

• To review immune-checkpoint inhibitors, focusing on anti-CTLA-4 and emerging therapies targeting PD-1/PD-L1.
• To discuss the therapeutic potential and autoimmune sequelae of these immunotherapies.
• To explore the balance between tumor immunity and autoimmunity using murine models.

Main Methods:

• Review of clinical trial data for anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
• Analysis of therapeutic combinations and their potential impact on autoimmune disorders.
• Application of regulatory T cell perturbation in murine models to study thyroid autoimmunity and tumor immunity.

Main Results:

• Anti-CTLA-4 therapy, while effective, is associated with significant immune-related adverse events.
• Combination therapies involving anti-CTLA-4 and agents targeting PD-1/PD-L1 are under investigation to improve overall survival.
• Murine models are used to simulate clinical scenarios and investigate the interplay between tumor immunity and induced autoimmunity.

Conclusions:

• Immune-checkpoint inhibitors represent a significant advancement in cancer immunotherapy, but managing irAEs remains crucial.
• Combination strategies hold promise for enhancing treatment efficacy and survival rates.
• Further research, including preclinical models, is essential to understand and balance anti-tumor responses with the risk of autoimmune complications.